Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The medical device maker posted another solid quarter and has high hopes for product launches on the way.

Medtronic's Q2 Results Weren't Splashy but Beat Expectations

Medtronic (MDT) demonstrates improved performances at CER, banking on growth in all major business segments and geographies.

Medtronic (MDT) Beats on Q2 Earnings, Ups FY20 EPS Guidance

Medtronic (NYSE: MDT) reported second-quarterly earnings of $1.31 per share on Tuesday, which beat the analyst consensus estimate of $1.28 by 2.34%.

Medtronic Reports Q2 Earnings Beat, Raises Guidance

Medtronic earnings and sales narrowly topped fiscal Q2 views for the medical technology giant. Shares edged higher, signal a move into a buy zone after a breakout attempt Monday.

Medtronic Earnings Edge Past Views; Medtech Giant Eyes Buy Zone

Shares of Medtronic PLC MDT, -0.72% surged 2.4% in premarket trading Tuesday, after the medical technology company reported fiscal second-quarter earnings that rose above expectations, and raised its full-year profit outlook, but the stock slipped 1.1% in premarket trading to extend a pullback from the previous session's all-time intraday high.

Medtronic's stock surges after earnings rise above expectations, and outlook raised

Medical device maker Medtronic reported a 22.3% jump in quarterly profit on Tuesday.

Medical device maker Medtronic's quarterly profit rises 22%

DUBLIN, Nov.  19, 2019  (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019.

Medtronic Reports Second Quarter Financial Results

In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.

Medtronic (MDT) to Report Q2 Earnings: What's in Store?

Arconic

Hewlett Packard

Nasdaq

Target

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading Near 52-Week High With More Room to Run.

The Medtronic 2019 Integrated Performance Report Shares Progress on Pay Equity, Diversity in Management Roles, Access to Healthcare, Environmental Performance, UN Sustainable Development Goals, and More

Medtronic Highlights Leadership in Inclusion, Diversity, and Equity in 2019 Integrated Performance Report

Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.

Medtronic (MDT) Releases Positive Study Results on Pacemaker

Data Published in    JACC: Clinical Electrophysiology    and to be Presented at American Heart Association Scientific Sessions Demonstrates the Potential of Investigational Algorithms in Medtronic Micra Pacemaker to Improve Synchrony and Cardiac Function in AV Block Patients

New Study Shows Promise in Treating More Patients with World’s Smallest Pacemaker

Longest-Term Data from a Real-World PAD Patient Population Presented at VIVA

Four-Year Data from the IN.PACT Global Study Highlight Durable Performance and Safety of IN.PACT™ Admiral™ DCB

Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Continues to Broaden Global Treatable Patient Population with Thoracic Aortic Disease

Medtronic Announces Shonin Approval and Launch of the Valiant Navion™ Thoracic Stent Graft System in Japan

The global robotic surgery device market is expected to surpass more than $7 billion by 2028, and Medtronic (MDT) just made a move to gain a bigger share.

Medtronic Introduces Robotics Challenger to Intuitive System

System Offers at Home Therapy Management for DBS patients  Using Patient-Friendly Consumer Technology

Medtronic Launches New Activa™ Patient Programmer for DBS Therapy

DUBLIN, Oct.  29, 2019  (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Medtronic Fully Implantable Left Ventricular Assist Device (LVAD) for patients with advanced heart failure, currently in development.

Medtronic Receives FDA “Breakthrough Device Designation” for Developing Fully Implantable Heart Pump

Booz Allen Hamilton Hld

Dick's Sporting Goods

Owens Corning

Stocks with a strong history of dividend growth year over year form a healthy portfolio with a greater scope of capital appreciation.

5 Solid Dividend Growth Stocks for Higher Returns

DUBLIN, Oct.  21, 2019  (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT) today announced that Sean Salmon, previously Senior Vice President (SVP) and President, Coronary and Structural Heart (CSH) within the Cardiac and Vascular Group of Medtronic, has been named Executive Vice President (EVP) and Group President of Medtronic Diabetes, effective today. Salmon will serve on the company’s Executive Committee and succeeds Hooman Hakami, who is leaving Medtronic.

Sean Salmon Named Executive Vice President and  Group President of Medtronic Diabetes

Canopy Growth

Quanterix

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

3 Medical Product Stocks - Likely to Beat This Earnings Season

The GI Genius™ Intelligent Endoscopy Module Transforms Colorectal Cancer Detection Benefitting Patients and Gastroenterologists The GI Genius™ Intelligent Endoscopy Module Transforms Colorectal Cancer Detection Benefitting Patients and Gastroenterologists

Medtronic Launches the First Artificial Intelligence System for Colonoscopy at United European Gastroenterology Week 2019

CoreLogic

Merck

The number of new job additions in September can be considered decent as new positions were created across various key sectors. The unemployment rate in the country also stooped to a five-decade low, which is undoubtedly good news.

4 Stocks From Highest Job-Creating Sectors in September

Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.

Medtronic Submits Two Pelvic Health Devices for FDA's PMA

DUBLIN, Oct.  09, 2019  (GLOBE NEWSWIRE) --  Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) has classified the company’s voluntary field action initiated in March 2019 related to the 6F Sherpa™ NX Active Coronary Guide Catheter as a Class I recall. The catheter is used during coronary and peripheral interventional procedures. This issue does not affect the Medtronic Launcher® Coronary Guide Catheter or other Medtronic coronary stents, balloons or implantable devices.

FDA Classifies Medtronic Sherpa Delivery Catheter Field Action Initiated in March 2019 as Class I Recall

This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.

News for Medtronic Stock (MDT)